Total amount: € 0,00
HOW TO ORDER
A Journal on Phlebology
Acta Phlebologica 2002 December;3(3):125-30
language: English, Italian
Compression theraphy improves the quality of life in patients with venous insufficiency
Arpaia G. 1, 2, Mastrogiacomo O. 1, 2, Peliccioni E. 3, Scondotto G. 3, Cimminiello C. 1
1 Vascular Unit, 2nd Department of Medicine, Civil Hospital, Vimercate-Milano, Italy;
2 Research Centre of Compression Therapy, “CIZETA Medicali”, Cuggiono-Milano, Italy;
3 Angiology Service and Day Hospital Poliambulatorio “Mengoli”, Bologna, Italy
AIM: The lack of compliance to compression therapy represents one of the main obstacles to its application, despite its being the most effective medical therapy for venous disorders. In Western societies, 30% of men and 50% of women can be defined as having some kind of venous disorder. However, according to an Italian study, only 25% of patients with venous disorders are prescribed compression therapy; of these only 70% comply with treatment. A variety of causes have been cited for lack of compliance, including hot weather, discomfort of wearing elastic support hosiery, lack of appropriate sizes, cost to the patient.
METHODS: In preparation for a new line of therapeutic hosiery designed according to GGG-RAL norms, measurement was taken of the lower limbs of patients attending an angiology outpatient clinic. From this anthropometric data pool new garment size and anatomical tables were generated based on which a line of compression hosiery was developed that incorporated advanced features of wearability and transpiration. The study was conducted on 50 consecutively enrolled patients with chronic venous insufficiency (CEAP classes 0, 1, 2, 3). The patients were given compression class 1 elastic stockings and asked to evaluate changes in symptoms according to numerical and analog scales and to respond to quality of life items (questionnaire SF36); compliance to treatment was also assessed. The duration of the study was 2 months.
RESULTS: The compliance rate was 80%. Results from the symptoms scales confirmed the clinical efficacy of treatment, which was observable after the first 30 days of therapy.
CONCLUSIONS: The impact on quality of life showed improvement in mean percentage values, which, however, did not reach statistical significance.